Last reviewed · How we verify

NCT03950648

Spatial Cognitive Training for Chronic Vestibular Disorders

Withdrawn NA Last updated 10 September 2020
What this trial tests

NA trial testing Spatial Cognitive Training in Vestibular Abnormality. Withdrawn.

Timeline
1 June 2020
Primary endpoint
30 June 2020
31 August 2020

Quick facts

Lead sponsorUniversity of Pittsburgh
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date1 June 2020
Primary completion30 June 2020
Estimated completion31 August 2020

Drugs / interventions tested

Conditions studied

Sponsor

University of Pittsburgh

Who can join

18 and older, any sex, with Vestibular Abnormality or Cognitive Training. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study the investigators propose to apply cognitive training, which has been largely used in the realm of age-related cognitive decline, dementia, and Alzheimer's disease, in a novel clinical context to individuals with vestibular impairment. In prior work the investigators observed that individuals with vestibular loss have evidence of spatial cognitive impairment. The investigators plan to evaluate the preliminary efficacy and feasibility of a cognitive training program in a sample of participants with chronic vestibular impairment who display deficits in spatial ability. The cognitive training program will focus on visuospatial skills and will be used as an adjunct to traditional vestibular physical therapy (VPT).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Pittsburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03950648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing